Use your antibodies-online credentials, if available.
抗Human ROS1 抗体:
抗Rat (Rattus) ROS1 抗体:
抗Mouse (Murine) ROS1 抗体:
Human Polyclonal ROS1 Primary Antibody for ELISA, WB - ABIN4242203
Shiffman, Ellis, Rowland, Malloy, Luke, Iakoubova, Pullinger, Cassano, Aouizerat, Fenwick, Reitz, Catanese, Leong, Zellner, Sninsky, Topol, Devlin, Kane: Identification of four gene variants associated with myocardial infarction. in American journal of human genetics 2005
ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations.
identified four genomic rearrangements involving the genes BRAF, RET, and ROS1
Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK (显示 ALK 抗体)-, ROS1-, RET (显示 RET 抗体)-Rearrangements in Non-Small-Cell Lung Cancer and ERG (显示 ERG 抗体)-Rearrangements in Prostate Cancer.(
MFA has a protective effect on alcohol-induced liver injury, which may be related to its antioxidant,anti-inflammatory,lipid-eliminating properties and its ability to regulate the NOX4 (显示 NOX4 抗体)/ROS-MAPK (显示 MAPK1 抗体) signalling pathway.
Female, cribriform structure and presence of psammoma body were the three most powerful indicator of ROS1 rearrangement status, and predictive formula was helpful in screening ROS1-rearranged non-small-cell lung carcinomas, especially for ROS1 immunochemistry equivocal cases.
report adds the ZCCHC8-ROS1 fusion as oncogenic driver in GBM and supports the role of ROS1 activation in the pathogenesis of a subset of glioblastoma
ROS1 mutation is associated with response to chemotherapy in lung adenocarcinoma.
A subset of ALK (显示 ALK 抗体)-negative inflammatory myofibroblastic tumour (IMT) have rearrangement of ROS1, ETV6 (显示 ETV6 抗体) or NTRK3 (显示 NTRK3 抗体) as a possible oncogenic mechanism.
This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.
High CEP85L-ROS1 expression is associated with neoplasms.
GPX1-dependent alterations in oxido-reductive stress promote ROS1 activation and mediate vascular remodeling.
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
c-ros and its ligand may be necessary for differentiation of epithelia I and II in mouse.
This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor.
c-Ros receptor tyrosine kinase
, proto-oncogene c-Ros
, proto-oncogene c-Ros-1
, proto-oncogene tyrosine-protein kinase ROS
, receptor tyrosine kinase c-ros oncogene 1
, transmembrane tyrosine-specific protein kinase
, v-ros UR2 sarcoma virus oncogene homolog 1
, v-ros avian UR2 sarcoma virus oncogene homolog 1
, Ros1 proto-oncogene
, heart - derived c - ros - 1 proto - oncogene
, proto-oncogene c-ros